Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
July-2017 Volume 16 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
July-2017 Volume 16 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article

Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways

  • Authors:
    • Meilan Xue
    • Yinlin Ge
    • Chundong Yu
    • Zheng Zheng
    • Xinjia He
    • Jinglan Zhao
  • View Affiliations / Copyright

    Affiliations: Department of Biochemistry and Molecular Biology, Medical College, Qingdao University, Qingdao, Shandong 266021, P.R. China, Department of Laboratory, Women and Children's Hospital of Qingdao, Qingdao, Shandong 266034, P.R. China, Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Cardiothoracic Surgery, Qingdao Center Medical Group, Qingdao, Shandong 266033, P.R. China
  • Pages: 978-982
    |
    Published online on: June 1, 2017
       https://doi.org/10.3892/mmr.2017.6678
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

In the present study, the antitumor effect of n‑3 fatty acid was evaluated, and the effect of docosahexaenoic acid (DHA) on the induction of apoptosis and its underlying mechanism were examined. Flow cytometry and western blot analysis were performed to analyze apoptosis and the expression of protein factors in human breast cancer cells. The data revealed that DHA inhibited the viability of MCF‑7 breast cancer cells in vitro, and promoted cell death by the induction of apoptosis. DHA decreased the expression of B‑cell lymphoma 2 (Bcl‑2), whereas the expression of Bcl‑2‑associated X protein was increased. DHA was also shown to promote the release of Smac/Diablo and cytochrome c from the mitochondria. DHA increased the levels of cleaved caspase‑8, ‑9 and ‑3. Additionally, the protein expression of tumor necrosis factor‑related apoptosis‑inducing ligand, death receptor 4 and Fas were increased following DHA treatment. In conclusion, DHA caused apoptosis of the human breast cancer cells in vitro through the death receptor and mitochondria‑mediated pathways. The results of this study encourage further investigation of the effect of fish oil on the prevention and treatment of human breast cancer.

Introduction

The n-3 and n-6 fatty acids (FAs) are essential and important to human health. However, there is a disproportionally high proportion of n-6 FAs and low proportion of n-3 FAs in our current dietary structure. This results in a high ratio of n-6/n-3, which is associated with cardiovascular disease, inflammation and cancer (1–3). The n-3 FAs are long-chain polyunsaturated FAs. Eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3) are two important n-3 FAs. The primary dietary source of these is oily fish (4). Investigations in human populations have revealed that a high consumption of fish or fish oils can decrease the risk of breast, prostate and colon cancer (5,6). Previous laboratory experiments have shown that n-3 FAs can inhibit the initiation and development of breast cancer in vivo (7,8), although others have failed to identify a significant association.

The n-3 FAs have a number of biological effects, and effects of n-3 FAs on cancer suppression have been suggested (9,10), with n-3 FAs affecting the apoptosis, proliferation, invasion and metastasis of cancer cells. There are several signaling pathways involved in the effects of n-3 FAs, including protein kinase C, extracellular signal-regulated kinase (ERK) 1/2, ras and nuclear factor (NF)-κB (11–14). However, the effect of n-3 FAs on the death receptor-mediated pathways and its molecular mechanisms remain to be fully elucidated.

In the present study, the antitumor effect of n-3 FAs was investigated, with a focus on the apoptosis-inducing effects of DHA on MCF-7 human breast cancer cells in culture. An improved understanding of the mechanism underlying the antitumor effects of n-3 FAs may assist in developing novel tumor treatment strategies involving the use of fish oil as a dietary supplement.

Materials and methods

Chemicals and reagents

DHA, EPA, linoleic acid (18:2n-6) and arachidonic acid (20:4n-6) in fetal bovine serum (FBS) were purchased from Sigma-Aldrich; Merck Millipore (Darmstadt, Germany). Anti-β-actin antibody and horseradish peroxidase (HRP)-conjugated anti-rabbit, anti-mouse and anti-goat IgG were obtained from Amersham; GE Healthcare Life Sciences (Chalfont, UK; 600567, RPN4301, RPN4201 and PA42002). Antibodies against cytochrome c and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were obtained from BD Pharmingen (Franklin Lake, NJ, USA; 558700 and 556468). The antibodies against cleaved caspase-3, cleaved caspase-8 and cleaved caspase-9 were obtained from Cell Signaling Technology, Inc. (Beverly, MA, USA; 9661S, 9496S and 9501S). Antibodies against death receptor (DR) 4 and 5 were purchased from Imgenex; Novus Biologicals LLC (Littleton, CO, USA; NB100-56747 and NB-100-55744). Antibodies against B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), Fas, Fas ligand (FasL) and Smac/Diablo were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA; sc-509, sc-7480, sc-8009, sc-33716 and sc-393118).

Cell culture

The MCF-7 breast cancer cells were purchased from Shanghai Life Science of Chinese Academy of Sciences (Shanghai, China). The MCF-7 cells were cultured in Roswell Park Memorial Institute 1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA), supplemented with 10% heat-inactivated FBS (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA), in an incubator at 37°C with 5% CO2 and 98% relative humidity. The MCF-7 cells were seeded in 6-well plates in routine cultivation. Cells in the exponential growth phrase were used in the subsequent experiments.

3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay

The MTT (Roche Diagnostics, Basel, Switzerland) assay was performed as previously described (15). The MCF-7 cells (1×104 cells per well) were seeded in triplicate on a 96-well plate and cultured overnight prior to treatment with 25, 50 and 100 µM DHA or EPA for 24 or 72 h. Following incubation, MTT dye was added and the mixture was incubated for 4 h at 37°C. The supernatant was removed and 150 µl DMSO was added to each well to dissolve the crystals completely, following which an ELISA reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to determine the absorbance at 490 nm. The results are expressed as the percentage of inhibition, which led to a reduction in absorbance by DHA, compared with that in the control group.

Analysis of apoptosis using flow cytometry

An Annexin V-FITC apoptosis detection kit was used for the analysis of apoptosis (Invitrogen; Thermo Fisher Scientific, Inc.). DHA concentrations of 25, 50 and 100 µM were used to treat the MCF-7 cells (1×106 cells/ml), respectively, for 48 h at 37°C. The cells were digested in trypsin, washed twice with PBS and resuspended in 500 µl binding buffer. The cell suspensions were then treated with 5 µl of Annexin V-FITC and 5 µl propidium iodide (PI). Following treatment for 10 min at room temperature, the apoptosis of the cells were determined immediately using flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA).

Analysis of proteins using western blot analysis

The MCF-7 cells were grown on 6-well plates (1×106 cells/ml), to which 25, 50 and 100 µM DHA were added and incubated for 48 h. The cells were lysed in 0.5 ml lysis buffer (PBS containing 1% Triton X-100 and 1 mM PMSF) at 4°C for 10 min. The concentrations of protein were then measured using a BCA assay. For western blot analysis, cell lysates (5 µg) from the cancer cell culture were subjected to 12% SDS-PAGE, transferred to polyvinylidene difluoride membranes, and blocked with 5% nonfat milk in TBS-Tween buffer (TBST; 20-mM Tris-HCl, 120 mMNaCl, 0.1% Tween-20) for 1 has described previously (16). Membranes were incubated with primary antibodies against cleaved caspase-3, -8 −9 (dilution, 1:500), Bcl-2, Bax, Fas, FasL (dilution, 1:1,000), Smac (dilution, 1:400), DR4 and DR5 (dilution, 1:200) at 4°C overnight. Following 3 washes (5 min each) with TBST, the membranes were incubated with an appropriate secondary antibody for 2 h at room temperature. Membranes were washed 3 times (5 min each) with TBST, and protein expression was quantified using a Gel EDAS analysis system (Cold Spring USA Corporation, Cherry Hill, NJ, USA) and Gel-Pro Analyzer 3.1 software (Media Cybernetics, Inc., Rockville, MD, USA).

Statistical analysis

Statistical analyses were performed using one-way analysis of variance with SPSS 11.0 software (SPSS, Inc., Chicago, IL, USA). Comparison between groups was performed using Duncan's test. All data are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.

Results

Inhibitory effect of DHA on the growth of breast cancer cells

The effect of DHA on the viability of MCF-7 cells was initially determined using an MTT assay. As shown in Fig. 1, DHA treatment decreased the viability of the MCF-7 cells (P<0.05). Following treatment with 100 µM DHA for 72 h, the proliferation of the MCF-7 cells was inhibited by 45.5%.

Figure 1.

Inhibitory effect of DHA on the growth of MCF-7 cells. The effect of DHA on the viability of cultured MCF-7 cells was determined using a3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide assay. Treatment with 25, 50, 100 and 200 µM DHA reduced the viability of the MCF-7 cells (P<0.05). Following treatment with 100 µM DHA for 72 h, the proliferation rate of the MCF-7 cells was inhibited by 45.5%. *P<0.05, vs. control. DHA, docosahexaenoic acid.

DHA induces apoptosis of breast cancer cells

The apoptosis of cells was estimated using flow cytometry. The apoptotic rates were higher in the DHA-treated cells, compared with that in the control (Fig. 2). Following treatment with DHA (25, 50 and 100 µM) for 48 h, the proportions of early apoptotic MCF-7 cells were 26.7, 38.1 and 50.6%, respectively (P<0.05).

Figure 2.

Flow cytometric analysis of the apoptosis of MCF-7 cells treated with DHA for 48 h. (A) Control; (B) 25 µM DHA; (C) 50 µM DHA; (D) 100 µM DHA. MCF-7 cells were stained with Annexin V-FITC and propidium iodide. Following treatment with DHA, the early apoptotic rates of the MCF-7 cells were 26.7, 38.1 and 50.6% respectively, and were significantly increased, compared with that in the untreated cells (P<0.05). The gated quadrants were as follows: K1, Annexin V-/PI+, necrosis; K2, Annexin V+/PI+, late apoptosis and necrosis; K3, Annexin V-/PI-, normal cells without apoptosis or necrosis; K4, Annexin V+/PI-, early apoptosis. DHA, docosahexaenoic acid.

Effect of DHA on the expression of the Bcl-2 family proteins

The increased expression of Bax is reported as an apoptosis-signaling pathway in breast cancer cells and proteins of the Bcl-2 family are important factors in apoptosis regulation (17–19). In the present study, the expression levels of Bcl-2 and Bax were examined in MCF-7 cells following treatment with DHA. The expression of Bcl-2 was reduced and the expression of Bax was increased following DHA treatment. Therefore, the ratio of Bcl-2/Bax was decreased (Fig. 3).

Figure 3.

Expression of Bcl-2 and Bax in MCF-7 cells following treatment with DHA for 48 h, detected using western blot analysis. (A) Protein levels of Bcl-2 and Bax were measured using western blot analysis. Expression of β-actin was used as the internal control. (B) Relative expression levels of Bcl-2 and Bax and the expression ratio of the two are shown. DHA reduced the level of Bcl-2, increased the level of Bax and reduced the Bcl-2/Bax ratio. Lane 1, control cells; lanes 2–4, MCF-7 cells treated with 50, 100 and 200 µM DHA, respectively. *P<0.05 and **P<0.01, vs. control. Bcl-2, B-cell lymphoma 2; Bax, Bcl-2-associated X protein; DHA, docosahexaenoic acid.

DHA increases the activation of caspases

Caspases are central effectors in apoptosis. In order to identify the mechanisms responsible for DHA-induced apoptosis, the present study detected the levels of activated caspases using western blot analysis to identify the mechanism underlying the induction of apoptosis by DHA. Following treatment of the cells with DHA, the levels of cleavedcaspases-8, -9 and -3 were increased (Fig. 4).

Figure 4.

DHA induces increases in the levels of cleaved caspases in MCF-7 cells. Following treatment with DHA for 48 h, MCF-7 cell lysates were detected using western blot analysis. Images representative of three independent experiments are shown. The levels of cleaved caspases-8, -9 and -3 were increased following DNA treatment. Lane 1, control cells; lanes 2–4: MCF-7 cells treated with 50, 100 and 200 µM DHA, respectively. DHA, docosahexaenoic acid.

DHA induces the mitochondria to release cytochrome c and Smac/Diablo

In apoptosis, mitochondria release cytosolic cytochrome c and Smac/Diablo, which then activate caspase-9 (20). As DHA increased the activation of caspase-9, the levels of cytochrome c and Smac/Diablo in the cytoplasm were determined in the present study. As shown in Fig. 5, DHA treatment markedly increased the levels of cytoplasmic cytochrome c and Smac/Diablo. This suggested that DHA induced the mitochondria to release cytochrome c and Smac/Diablo.

Figure 5.

DHA increases the release of cytochrome c and Smac/Diablo from the mitochondria in MCF-7 cells. Cells were treated with 50, 100 and 200 µM DHA, respectively, for 48 h, then treated with subcellular fractionation. The levels of cytochrome c and Smac/Diablo in the resultant cytosolic fractions were detected using western blot analysis. Following treatment with DHA, the levels of cytochrome c and Smac/Diablo in the cytoplasm were increased. Lane 1, control cells; lanes 2–4, MCF-7 cells treated with 50, 100 and 200 µM DHA, respectively. DHA, docosahexaenoic acid.

DHA increases the expression of death receptors

Caspase-8 is involved in the death receptor-mediated apoptotic pathway. In the present study, DHA treatment increased the level of activated caspase-8; therefore, the levels of death receptors and membrane-bound death receptor ligands were determined. Following DHA intervention, the expression levels of Fas, DR4, and TRAIL were increased, whereas no significant changes in the expression levels of FasL or DR5were observed (Fig. 6).

Figure 6.

DHA increases the expression of cell death receptors and their ligands in MCF-7 cells. Following treatment with different concentrations of DHA, the protein levels of Fas, FasL, DR4, DR5 and TRAIL were measured using western blot analysis. The results showed that DHA treatment increased the expression levels of Fas, DR4, and TRAIL, whereas the expression levels of FasL and DR5 remained unchanged. Lane 1, control cells; lanes 2–4, MCF-7 cells treated with 50, 100 and 200 µM DHA, respectively. DHA, docosahexaenoic acid; FasL, Fas ligand; DR, death receptor; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.

Discussion

In the present study, it was found that DHA, an n-3FA, resulted in the inhibition of cell viability and the induction of cell apoptosis. These results confirmed and extended earlier observations (21–23) on the antitumor effect of n-3 FAs.

The results of previous studies revealed that the antitumor effect of DHA is due to the induction of apoptosis (21–23). There are also reports showing that EPA treatment of HL-60 cells induces the activation of caspase-3, -6, -8 and -9, and the release of cytochrome c from mitochondria (24). In the present study, the results of the flow cytometry confirmed that DHA treatment induced apoptosis of the breast cancer cells.

The exact role of n-3 FAs in the development, progression and prevention of breast cancer remains to be fully elucidated. The n-3 FAs are involved in the development and progression of tumors via multiple mechanisms. Several signaling pathways are associated with carcinogenesis and tumor progression by n-3 polyunsaturated FAs. For example, n-3FAscan downregulate and inactivate cellular signaling mediators, including protein kinase C, ras, ERK1/2, and NF-κB (11–14). In addition, n-3 FAs can affect prostate inflammation and carcinogenesis via the cyclooxygenase (COX)-2 enzymatic pathway (25). Kang et al (26) revealed that apoptosis was induced by DHA treatment in MCF-7 cells, and that DHA promoted the formation of reactive oxygen species (ROS) and activation of caspase-8. Previous studies have also suggested that DHA can improve the prognosis of patients with breast cancer following chemotherapy through increasing the formation of ROS (27). Dimri et al (28) found that dietary n-3 FAs suppressed the expression of enhancer of zeste homologue 2 (EZH2), and downregulated the expression of E-cadherin and insulin-like growth factor binding protein 3, which are targets of EZH2 in breast cancer cells. The other possible mechanism was associated with the inhibitory effect of n-3 FAs on the expression of COX, the p21 gene and the p53 gene (29). DHA and EPA have also been reported to downregulate cell surface expression of C-X-C chemokine receptor type 4 (CXCR4) and markedly decrease CXCR4-mediated cell migration in breast cells in vitro (30). The exact molecular mechanism underlying this signaling remains to be fully elucidated. Previously, it was reported that the proteins of the Bcl-2 family may be important in n-3 FA-induced cell death. In the present study, data revealed that DHA at concentrations of 25–100 µM increased the expression of Bax but reduced the expression of Bcl-2, increased the release of cytochrome c and Smac/Diablo from mitochondria, promoted the activation of caspases, and increased the levels of Fas, DR4 and TRAIL in MCF-7 breast cancer cells. These results suggested that DHA activated caspases and induced apoptosis through the mitochondria-mediated and death receptor-mediated apoptotic pathways.

The results of the present study indicated that further investigations are required to determine whether the supplementation of dietary n-3 FAs has an inhibitory effect on tumor growth in patients with breast cancer.

Acknowledgements

The present study was completed with the support of the Youth Science Fund Project of the Natural Science Foundation of China (grant no. 81502298), the Shandong Provincial Natural Science Foundation (grant nos. ZR2014JL056 and ZR2010CM010), the Development Project of Shandong Province Medical Science and Technology (2013WS0262), Qingdao Postdoctoral Application Research Project (grant no. 2015165), the Ministry of Education Key Laboratory Open Foundation of Marine Culture of China Ocean University (grant no. 2009001), and the Qingdao University Medical College Young Teachers Cultivation Project (grant no. 600201304).

References

1 

Umemoto N, Ishii H, Kamoi D, Aoyama T, Sakakibara T, Takahashi H, Tanaka A, Yasuda Y, Suzuki S, Matsubara T and Murohara T: Reverse association of omega-3/omega-6 polyunsaturated fatty acids ratios with carotid atherosclerosis in patients on hemodialysis. Atherosclerosis. 249:65–69. 2016. View Article : Google Scholar : PubMed/NCBI

2 

Molfino A, Gioia G, Fanelli Rossi F and Muscaritoli M: The role for dietary omega-3 fatty acids supplementation in older adults. Nutrients. 6:4058–4073. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Gomez-Candela C, Puchalt Roldan MC, Palma Milla S, Lopez Plaza B and Bermejo L: The role of omega-3 fatty acids in diets. J Am Coll Nutr. 34:(Suppl 1). S42–S47. 2015. View Article : Google Scholar

4 

Bartram HP, Gostner A, Scheppach W, Reddy BS, Rao CV, Dusel G, Richter F, Richter A and Kasper H: Effects of fish oil on rectal cell proliferation, mucosal fatty acids, and prostaglandin E2 release in healthy subjects. Gastroenterology. 105:1317–1322. 1993. View Article : Google Scholar : PubMed/NCBI

5 

Liu J and Ma DW: The role of n-3 polyunsaturated fatty acids in the prevention and treatment of breast cancer. Nutrients. 6:5184–5223. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Laviano A, Rianda S, Molfino A and Fanelli FR: Omega-3 fatty acids in cancer. Curr Opin Clin Nutr Metab Care. 16:156–161. 2013. View Article : Google Scholar : PubMed/NCBI

7 

Zhang F and Chen Y, Long J, Dong L, Wang Y and Chen Y: Effect of n-3 and n-6 polyunsaturated fatty acids on lipid metabolic genes and estrogen receptor expression in MCF-7 breast cancer cells. Clin Lab. 61:397–403. 2015. View Article : Google Scholar : PubMed/NCBI

8 

Xue M, Wang Q, Zhao J, Dong L, Ge Y, Hou L, Liu Y and Zheng Z: Docosahexaenoic acid inhibited the Wnt/β-catenin pathway and suppressed breast cancer cells in vitro and in vivo. J Nutr Biochem. 25:104–110. 2014. View Article : Google Scholar : PubMed/NCBI

9 

Larsson SC, Kumlin M, Ingelman-Sundberg M and Wolk A: Dietary long-chain n-3 fatty acids for the prevention of cancer: A review of potential mechanisms. Am J Clin Nutr. 79:935–945. 2004.PubMed/NCBI

10 

Chapkin RS, McMurray DN and Lupton JR: Colon cancer, fatty acids and anti-inflammatory compounds. Curr Opin Gastroenterol. 23:48–54. 2007. View Article : Google Scholar : PubMed/NCBI

11 

McCarty MF: Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. Med Hypotheses. 46:107–115. 1996. View Article : Google Scholar : PubMed/NCBI

12 

Collett ED, Davidson LA, Fan YY, Lupton JR and Chapkin RS: N-6 and n-3 polyunsaturated fatty acids differentially modulate oncogenic Ras activation in colonocytes. Am J Physiol Cell Physiol. 280:C1066–C1075. 2001.PubMed/NCBI

13 

Sauer LA, Blask DE and Dauchy RT: Dietary factors and growth and metabolism in experimental tumors. J Nutr Biochem. 18:637–649. 2007. View Article : Google Scholar : PubMed/NCBI

14 

Cavazos DA, Price RS, Apte SS and deGraffenried LA: Docosahexaenoic acid selectively induces human prostate cancer cell sensitivity to oxidative stress through modulation of NF-κB. Prostate. 71:1420–1428. 2001. View Article : Google Scholar

15 

Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of radiosensitivity. Cancer Res. 47:943–946. 1987.PubMed/NCBI

16 

Cho HJ, Kim WK, Kim EJ, Jung KC, Park S, Lee HS, Tyner AL and Park JH: Conjugated linoleic acid inhibits cell proliferation and ErbB3 signaling in HT-29 human colon cell line. Am J Physiol Gastrointest Liver Physiol. 284:G996–G1005. 2003. View Article : Google Scholar : PubMed/NCBI

17 

Choudhuri T, Pal S, Agwarwal ML, Das T and Sa G: Curcumin induces apoptosis in human breast cancer cells through p53-dependent Bax induction. FEBS Lett. 512:334–340. 2002. View Article : Google Scholar : PubMed/NCBI

18 

Bruey JM, Bruey-Sedano N, Luciano F, Zhai D, Balpai R, Xu C, Kress CL, Bailly-Maitre B, Li X, Osterman A, et al: Bcl-2 and Bcl-XL regulate proinflammatory caspase-1 activation by interaction with NALP1. Cell. 129:45–56. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Cho MY, Park SY, Park S, Lee YR, Han GD and Kim JA: Geranyl derivative of phloroacetophenone induces cancer cell-specific apoptosis through Bax-mediated mitochondrial pathway in MCF-7 human breast cancer cells. Biol Pharm Bull. 35:98–104. 2012. View Article : Google Scholar : PubMed/NCBI

20 

Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 91:479–489. 1997. View Article : Google Scholar : PubMed/NCBI

21 

Sun H, Berquin IM, Owens RT, O'Flaherty JT and Edwards IJ: Peroxisome proliferator-activated receptor gamma-mediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res. 68:2912–2919. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Sauer LA, Dauchy RT, Blask DE, Krause JA, Davidson LK and Dauchy EM: Eicosapentaenoic acid suppresses cell proliferation in MCF-7 human breast cancer xenografts in nude rats via a pertussis toxin-sensitive signal transduction pathway. J Nutr. 135:2124–2129. 2005.PubMed/NCBI

23 

Siddiqui RA, Jenski LJ, Neff K, Harvey K, Kovacs RJ and Stillwell W: Docosahexanoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process. Biochim Biophys Acta. 1499:265–275. 2001. View Article : Google Scholar : PubMed/NCBI

24 

Arita K, Yamamoto Y, Takehara Y, Utsumi T, Kanno T, Miyaguchi C, Akiyama J, Yoshioka T and Utsumi K: Mechanisms of enhanced apoptosis in HL-60 cells by UV-irradiated n-3 and n-6 polyunsaturated fatty acids. Free Radic Biol Med. 35:189–199. 2003. View Article : Google Scholar : PubMed/NCBI

25 

Reese AC, Fradet V and Witte JS: Omega-3 fatty acids, genetic variants in COX-2 and prostate cancer. J Nutrigenet Nutrigenomics. 2:149–158. 2009. View Article : Google Scholar : PubMed/NCBI

26 

Kang KS, Wang P, Yamabe N, Fukui M, Jay T and Zhu BT: Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase 8 activation. PLoS One. 5:e102962010. View Article : Google Scholar : PubMed/NCBI

27 

Bougnoux P, Hajjaji N, Ferrasson MN, Giraudeau B, Couet C and Le Floch O: Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: A phase II trial. Br J Cancer. 101:1978–1985. 2009. View Article : Google Scholar : PubMed/NCBI

28 

Dimri M, Bommi PV, Sahasrabuddhe AA, Khandekar JD and Dimri GP: Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis. 31:489–495. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Rose DP and Connolly JM: Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids. Nutr Cancer. 37:119–127. 2000. View Article : Google Scholar : PubMed/NCBI

30 

Altenburg JD and Siddiqui RA: Omega-3 polyunsaturated fatty acids down-modulate CXCR4 expression and function in MDA-MB-231 breast cancer cells. Mol Cancer Res. 7:1013–1020. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Xue M, Ge Y, Yu C, Zheng Z, He X and Zhao J: Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways. Mol Med Rep 16: 978-982, 2017.
APA
Xue, M., Ge, Y., Yu, C., Zheng, Z., He, X., & Zhao, J. (2017). Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways. Molecular Medicine Reports, 16, 978-982. https://doi.org/10.3892/mmr.2017.6678
MLA
Xue, M., Ge, Y., Yu, C., Zheng, Z., He, X., Zhao, J."Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways". Molecular Medicine Reports 16.1 (2017): 978-982.
Chicago
Xue, M., Ge, Y., Yu, C., Zheng, Z., He, X., Zhao, J."Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways". Molecular Medicine Reports 16, no. 1 (2017): 978-982. https://doi.org/10.3892/mmr.2017.6678
Copy and paste a formatted citation
x
Spandidos Publications style
Xue M, Ge Y, Yu C, Zheng Z, He X and Zhao J: Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways. Mol Med Rep 16: 978-982, 2017.
APA
Xue, M., Ge, Y., Yu, C., Zheng, Z., He, X., & Zhao, J. (2017). Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways. Molecular Medicine Reports, 16, 978-982. https://doi.org/10.3892/mmr.2017.6678
MLA
Xue, M., Ge, Y., Yu, C., Zheng, Z., He, X., Zhao, J."Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways". Molecular Medicine Reports 16.1 (2017): 978-982.
Chicago
Xue, M., Ge, Y., Yu, C., Zheng, Z., He, X., Zhao, J."Apoptosis is induced by docosahexaenoic acid in breast cancer cells via death receptor and mitochondria-mediated pathways". Molecular Medicine Reports 16, no. 1 (2017): 978-982. https://doi.org/10.3892/mmr.2017.6678
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team